Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew A Wozniak

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of the American Geriatrics Society|January 20, 2007
Viral infection and cognitive declineRuth F Itzhaki, Matthew A Wozniak
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 5, 2010
Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease?Ruth F Itzhaki, Matthew A Wozniak
Rejuvenation Research|March 11, 2008
Alzheimer's disease-like changes in herpes simplex virus type 1 infected cells: the case for antiviral therapyRuth F Itzhaki, Matthew A Wozniak
Journal of Alzheimer'S Disease : JAD|May 20, 2008
Herpes simplex virus type 1 in Alzheimer's disease: the enemy withinRuth F Itzhaki, Matthew A Wozniak
Journal of Neuroimmunology|February 7, 2013
Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1Matthew A Wozniak, Ruth F Itzhaki
Therapeutic Advances in Neurological Disorders|December 24, 2010
Antiviral agents in Alzheimer's disease: hope for the future?Matthew A Wozniak, Ruth F Itzhaki
Progress in Lipid Research|January 13, 2006
Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disordersRuth F Itzhaki, Matthew A Wozniak
Future Microbiology|March 8, 2012
Could antivirals be used to treat Alzheimer's disease?Ruth F Itzhaki, Matthew A Wozniak
Journal of Neuroimmunology|November 6, 2004
Alzheimer's disease, the neuroimmune axis, and viral infectionRuth F Itzhaki, Matthew A Wozniak
Neurobiology of Aging|October 24, 2002
Inflammatory consequences: benevolent, or virulent?Ruth F Itzhaki, Matthew A Wozniak, Curtis B Dobson
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of the American Geriatrics Society|January 20, 2007
Viral infection and cognitive declineRuth F Itzhaki, Matthew A Wozniak
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|February 5, 2010
Alzheimer's disease and infection: Do infectious agents contribute to progression of Alzheimer's disease?Ruth F Itzhaki, Matthew A Wozniak
Rejuvenation Research|March 11, 2008
Alzheimer's disease-like changes in herpes simplex virus type 1 infected cells: the case for antiviral therapyRuth F Itzhaki, Matthew A Wozniak
Journal of Alzheimer'S Disease : JAD|May 20, 2008
Herpes simplex virus type 1 in Alzheimer's disease: the enemy withinRuth F Itzhaki, Matthew A Wozniak
Journal of Neuroimmunology|February 7, 2013
Intravenous immunoglobulin reduces β amyloid and abnormal tau formation caused by herpes simplex virus type 1Matthew A Wozniak, Ruth F Itzhaki
Therapeutic Advances in Neurological Disorders|December 24, 2010
Antiviral agents in Alzheimer's disease: hope for the future?Matthew A Wozniak, Ruth F Itzhaki
Progress in Lipid Research|January 13, 2006
Herpes simplex virus type 1, apolipoprotein E, and cholesterol: a dangerous liaison in Alzheimer's disease and other disordersRuth F Itzhaki, Matthew A Wozniak
Future Microbiology|March 8, 2012
Could antivirals be used to treat Alzheimer's disease?Ruth F Itzhaki, Matthew A Wozniak
Journal of Neuroimmunology|November 6, 2004
Alzheimer's disease, the neuroimmune axis, and viral infectionRuth F Itzhaki, Matthew A Wozniak
Neurobiology of Aging|October 24, 2002
Inflammatory consequences: benevolent, or virulent?Ruth F Itzhaki, Matthew A Wozniak, Curtis B Dobson
Pageof 3